The cell therapy company Kyverna Therapeutics (Emeryville, California) has closed an oversubscribed $85 million Series B funding round led by Northpond Ventures. The company plans to use the funding to launch a Phase 2 trial for its lead asset, KYV-101, in the first half of 2022. KYV-101 is an autologous anti-CD19 chimeric antigen receptor T-cell…
SimBioSys secures $15 million in Series A funding for computational oncology software
The developer of a cloud-based application for oncology care and research, SimBioSys, has raised $15 million in Series A funding. Genoa Ventures and Northpond Ventures led the funding round, which also involved AV8 Ventures, Heritage Medical Group, and Mayo Clinic. SimBioSys also announced that existing investors and its founders participated in the financing, raising a total of $21 million. The company…